Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Not applicable Interventional Results available

Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy

NCT05849103
View directory record Official record
Conditions
Hypertension, Pregnancy-Induced, Postpartum Preeclampsia, Hypertension; Maternal
Interventions
Blood Pressure Control Targets, Hypertension Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Withdrawn Not applicable Interventional

Contingency Management for Smoking Cessation in Pregnant Minority Women

NCT02195570
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Quit Smoking Now (QSN), Prize-based Contingency Management (CM)
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 23, 2026, 8:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Remote Incentives for Smoking Cessation Among AN Pregnant Women

NCT05019170
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Smartphone-based Financial Incentives, Best Practices
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Anchorage, Alaska • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 23, 2026, 8:26 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Prenatal Exposure Effects Psychophysiology Study

NCT01134770
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

NCT02517593
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation

NCT01079923
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Single High Dose Cholecalciferol, Daily Dose Cholecalciferol
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estradiol-Receptor Blockade in Older Men and Women

NCT02271282
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Toremifene, Placebo, GHRH/Ghrelin combined Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk

NCT06612879
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TRE: Microbiome, Metabolic Health and Bone

NCT05548517
View directory record Official record
Conditions
Weight Loss, Time Restricted Feeding, Bone Loss
Interventions
Time Restricted Eating (TRE), Calorie Restriction
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years to 79 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 4 Interventional

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610
View directory record Official record
Conditions
HIV Infection
Interventions
Nelfinavir mesylate, 625 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 23, 2026, 8:26 PM EDT
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 23, 2026, 8:26 PM EDT
Terminated Phase 1 Interventional Results available

Effects of Denosumab on the Pharmacokinetics of Etanercept

NCT01294397
View directory record Official record
Conditions
Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions
Etanercept, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Text Messages Into the Mothers and Babies Course

NCT03420755
View directory record Official record
Conditions
Perinatal Depression, Postpartum Depression
Interventions
Mothers and Babies 1-on-1, Mothers and Babies Plus Text
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 23, 2026, 8:26 PM EDT
Not listed No phase listed Observational

A Single Site Prospective, Non-randomized Study of Partial Breast Intracavitary Brachytherapy Devices to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.

NCT01813825
View directory record Official record
Conditions
This Study Has Been Designed to Compile Information on the Efficacy of the Partial Breast Intracavitary Brachytherapy in the Post Market Setting.
Interventions
Registry
Other
Lead sponsor
St. Vincent's Medical Center
Other
Eligibility
45 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Bridgeport, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Oct 23, 2026, 8:26 PM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 23, 2026, 8:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT05086315
View directory record Official record
Conditions
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions
SAR443579
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Ribociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 23, 2026, 8:26 PM EDT